

BIOSIMILARS

**A Guide to Regulatory and
Intellectual Property Issues**

GOODWIN

PROCTER

Boston | Hong Kong | London | Los Angeles | New York | San Francisco | Silicon Valley | Washington DC
www.goodwinprocter.com

BIOSIMILARS

A Guide to Regulatory and Intellectual Property Issues

Elaine Herrmann Blais

617.570.1205

eblais@goodwinprocter.com

Robert V. Cerwinski

212.459.7240

rcerwinski@goodwinprocter.com

Joseph B. Crystal

212.459.7353

jcystal@goodwinprocter.com

Marta E. Delsignore

212.813.8822

mdelsignore@goodwinprocter.com

Robert Frederickson III

617.570.1947

rfrederickson@goodwinprocter.com

Duncan A. Greenhalgh

617.570.1299

dgreenhalgh@goodwinprocter.com

Theresa C. Kavanaugh

617.570.8743

tkavanaugh@goodwinprocter.com

Thomas Lavery

212.459.7160

tlavery@goodwinprocter.com

Ginger B. Mimier

617.570.8227

gmimier@goodwinprocter.com

Nicholas K. Mitrokostas

617.570.1913

nmitrokostas@goodwinprocter.com

Emily L. Rapalino

617.570.1938

erapalino@goodwinprocter.com

Frederick H. Rein

212.813.8864

frein@goodwinprocter.com

Joshua Weinger

617.570.8361

jweinger@goodwinprocter.com

April B. Weisbruch

202.346.4306

aweisbruch@goodwinprocter.com

Daryl L. Wiesen

617.570.1396

dwiesen@goodwinprocter.com

Aviv A. Zalcenstein

212.813.7355

azalcenstein@goodwinprocter.com

TABLE OF CONTENTS

INTRODUCTION	1
MARKET DEVELOPMENTS FOR BIOSIMILARS	2
The Current Market for Biologics	2
The Market Potential for Biosimilars	4
Challenges and Opportunities for Biosimilar Manufacturers	8
Slow Uptake In Europe: Will the U.S. Follow?	26
APPROVAL PATHWAYS AND TIMELINES FOR FOLLOW-ON BIOLOGICS IN THE U.S.	28
Biosimilar Application Under 262(k)	28
Definition of Key Terms	28
Contents of Application	28
Timing of Approval	29
Biologics License Application Under Section 262(a)	30
Abbreviated New Drug Application	31
Comparison of Approval Pathways and Timelines	31
Litigation Under the BPCIA	34
Timeline for Pre-Litigation Disclosure Under BPCIA	34
Preliminary Injunctions Under the BPCIA	38
Use Of Post-Grant Patent Proceedings As A Tool In The Decision Making Process	39
BIOSIMILARS AT FDA	41
Biosimilar Application Activity at FDA	41
FDA Guidances for Biosimilar Applications	41
FDA Will Take Similar Approach to EMA When Approving Biosimilars	44
FDA Likely to Require Substantial Clinical Data for "Interchangeable" Biosimilars	44
BIOSIMILARS OUTSIDE OF THE U.S.	46
Europe	46
India	48
Japan	48
South Korea	49

RECENT LEGAL DEVELOPMENTS POTENTIALLY IMPACTING BIOSIMILARS51
Patent Eligibility Under the Supreme Court's Decisions in *Mayo* and *Myriad*.....51
Recent Developments in the Law of Patent Eligibility Following *Mayo* and *Myriad*.....51
Other Recent Case Law Affecting the Validity and Enforceability of U.S. Patent Rights53
Regulatory Developments at the PTO and FDA.....54
Pending Legislation: Statehouse Substitution Battles.....56
APPENDIX MATERIALS TABS 1 - 3

APPENDIX MATERIALS

TAB

U.S.

1

42 U.S.C. § 262

United States Patent and Trademark Office, 2014 Interim Guidelines on Patent Subject Matter Eligibility, 79 Fed. Reg. 74618, December 2014

FDA Guidance: Quality Considerations in Demonstrating Biosimilarity to a Reference Protein Product, February 2012

FDA Guidance: Scientific Considerations in Demonstrating Biosimilarity to a Reference Product, February 2012

FDA Guidance: Biosimilars: Questions and Answers Regarding Implementation of the Biologics Price Competition and Innovation Act of 2009, February 2012

FDA Guidance: Formal Meetings between the FDA and Biosimilar Biotechnical Product Sponsors or Applicants, April 2013

FDA Guidance: Clinical Pharmacology Data to Support a Demonstration of Biosimilarity to a Reference Product, May 2014

FDA Guidance for Industry: Reference Product Exclusivity for Biologic Products Filed Under 351a of PHS Act, August 2014

Court Decision: *AbbVie Deutschland GmbH & Co. v. Janssen Biotech, Inc.*

Court Decision: *Alice Corp. v. CLS Bank Int'l*

Court Decision: *Ariosa Diagnostics, Inc. (f/k/a Aria Diagnostics) v. Sequenom, Inc.*

Court Decision: *Association for Molecular Pathology v. Myriad Genetics, Inc.*

Court Decision: *In re Roslin Institute*

Court Decision: *Mayo Collaborative Services v. Prometheus Laboratories, Inc.*

Court Decision: *Momenta Pharmaceuticals, Inc. v. Amphastar Pharmaceuticals, Inc.*

EMA

2

European Medicines Agency: Guideline on Similar Biological Medicinal Products, October 2014

European Medicines Agency: Guideline on Similar Biological Medicinal Products Containing Biotechnology-Derived Proteins as Active Substance: Quality Issues (Revision 1), May 2014

European Medicines Agency: Guideline on Similar Biological Medicinal Products Containing Biotechnology-Derived Proteins as Active Substance: Non-Clinical and Clinical Issues, February 2006

India

Government of India, Department of Biotechnology: Guidelines on Similar Biologics: Regulatory Requirements for Marketing Authorization in India, 2012

Japan

Guideline for the Quality, Safety, and Efficacy Assurance of Follow-on Biologics, March 2009

South Korea

Korea Food & Drug Administration: Evaluation Guidelines for Biosimilars, July 2009